Welty, Francine K., Mittleman, Murray A., Healy, Robert W., Muller, James E., and Shubrooks, Samuel J.
Journal of the American College of Cardiology; January 1994, Vol. 23 Issue: 1 p35-39, 5p
Objectives. The purpose of this study was to determine whether there are gender differences in the outcome of percutaneous transluminal coronary angioplasty performed for postmyocardial infarction ischemia.
Welty, Francine K., Wilson, Peter WF., Mittleman, Murray A., Sutherland, Patrice A., Matheney, Travis H., Lipinska, Izabella, Muller, James E., Levy, Daniel, and Tofler, Geoffrey H.
Journal of the American College of Cardiology; February 1995, Vol. 25 Issue: 2, Number 2 Supplement 1 p76A-77A, 2p
The recent findings that lipid lowering therapy reduces clinical events to a greater degree than it reduces stenosis severity suggest beneficial effects other than plaque regression. To determine if a favorable lipid profile is associated with decreased thrombotic tendency, we determined the relationship between two hemostatic risk factors, fibrinogen and plasminogen activator inhibitor (PAI-l), and LDL cholesterol (LDL-C) in 1,878 subjects free of cardiovascular disease in the Framingham Offspring Study. The subjects studied ranged from those with hypobetalipoproteinemia, a condition characterized by LDL-C≤70mg/dl, and a low incidence of thrombosis and coronary heart disease, to other LDL-C levels grouped by NCEP guidelines.LDL-C (mg/dl)<7070–99100129>130*p-valueNumber subjects41389653795Fibrinogen (mg/dl)264±54287±59297±57303±55<0.0001PAI-l antigen (ng/ml)14±927±1822±1723±46<0.0001*p-value for linear effect of LDL-C
Mittleman, Murray A., Gebara, Otavio C.E., Sutherland, Patrice, Matheney, Travis, Lipinska, Izabela, Welty, Francine K., Levy, Daniel, Wilson, Peter W.F., Muller, James E., and Tofler, Geoffrey H.
Journal of the American College of Cardiology; February 1995, Vol. 25 Issue: 2, Number 2 Supplement 1 p327A-328A, 2p
Hormone replacement therapy (HRT) is associated with a decreased risk of coronary heart disease (CHD) in postmenopausal women, but the mechanism of its protective effect is not fully characterized. To evaluate the relation ship between postmenopausal HRT and fibrinogen, an established hemostatic risk factor for CHD, we measured fibrinogen using the Clauss method in 858 women free of CHD in cycle 4 of the Framingham Offspring Study. The table shows mean ± SD fibrinogen levels for pre and postmeonopausal women according to use of HRTNFibrinogen (mg/dl)%Δp-valuePremenopause303289±53Postmenopause (No HRT)383313±58↑7.7%*< 0.001*Postmenopause (HRT)86284±44↓9.3%**< 0.001***Premenopause vs. Postmenopause (No HRT);**Postmenopause (No HRT) vs. Postmenopause (HRT) (Age adjusted)
Gebara, Otavio C.E., Walsh, Brian, Mittleman, Murray A., Greenberg, Louise, Welty, Francine K., Lipinska, Izabela, Feng, Da-Li, Sacks, Frank, and Tofler, Geoffrey H.
Journal of the American College of Cardiology; February 1995, Vol. 25 Issue: 2, Number 2 Supplement 1 p328A-328A, 1p
Estrogen usage in postmenopausal women is associated with a decrease in cardiovascular events, however the mechanism is not well characterized. Although observational studies suggest that estrogen may act in part through an improvement in fibrinolytic potential, this has not been established in placebo-controlled trials before and after estrogen therapy.